Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Treatment Efficacy of SAB-176 (a Quadrivalent Anti-seasonal Influenza Immunoglobulin Product) in an H1N1 Challenge Model in Healthy Adult Participants

NCT04850898 is registered in ClinicalTrials.gov with SAb Biotherapeutics, Inc. as lead sponsor.

NCT NCT04850898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04850898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Treatment Efficacy of SAB-176 (a Quadrivalent Anti-seasonal Influenza Immunoglobulin Product) in an H1N1 Challenge Model in Healthy Adult Participants
Lead sponsor
SAb Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 23, 2021
Completion date
October 8, 2021
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza a h1n1